- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CANO HEALTH Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 321,40 | -0,11 % | Intuitive Surgical's Record Cash Flow Gives It an Innovation Advantage | ||
| UNITEDHEALTH | 340,40 | +0,35 % | Billionaire David Tepper Sold Every Single Share of UnitedHealth in Q2. Here's Whether He Made a Costly Mistake. | ||
| THERMO FISHER | 537,20 | +0,04 % | Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside? | ||
| ATOSSA THERAPEUTICS | 2,240 | 0,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| CENTENE | 56,78 | +1,57 % | Centene: Deutliche Margenerholung - warum der Markt die neue Gewinnqualität noch immer unterschätzt | Centene verzeichnet eine klare Margenerholung im Kerngeschäft und erhöht seine Ergebnisziele, während die Bewertung im historischen Vergleich moderat bleibt. Die Aktie hat sich zwar bereits deutlich... ► Artikel lesen | |
| QUIDELORTHO | 12,645 | 0,00 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,630 | +0,19 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 1,080 | +1,89 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| NANO-X IMAGING | 0,832 | +0,23 % | Nano-X Imaging Ltd: Nanox to Report Second Quarter 2026 Financial Results on September 9, 2026 | ||
| FULGENT GENETICS | 16,900 | -0,59 % | Fulgent expects $330M-$340M 2026 revenue as billing transition lowers collection rates | ||
| LANTHEUS | 86,50 | -0,57 % | Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of TAUKLARIFY (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease | BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,726 | +2,02 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results | Advancing VMT-a-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject... ► Artikel lesen | |
| OMNICELL | 29,200 | +2,10 % | OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth | ||
| AMN HEALTHCARE SERVICES | 30,000 | 0,00 % | AMN Healthcare Services, Inc.: Amn Healthcare Announces Second Quarter 2026 Results | Quarterly revenue of $673 million and adjusted EBITDA of $73 million;
GAAP income of $0.53/share and adjusted EPS of $0.77
DALLAS, Aug. 6, 2026 /PRNewswire/ --... ► Artikel lesen |
Das Unternehmen CANO HEALTH INC kann der Branche Gesundheitswesen zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANO HEALTH INC finden Sie auf Wallstreet Online.